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Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease that causes severe 
disability and has no cure. Over the past 20 years, a variety of treatment options have evolved 
for  the  management  of  PAH.  With  an  expanded  therapeutic  armamentarium  come  more 
complex decisions regarding treatment options. Agent selection depends upon several factors 
including efficacy, side effect profile, and cost, as well as convenience of administration. We 
have undertaken a review of phosphodiesterase-5 (PDE-5) inhibitors in PAH with a focus on 
efficacy and safety. A literature search was conducted using the Medline and Cochrane Central 
Register of Controlled Trials databases (1966–February 2010) for relevant randomized clinical 
studies. Overall, 10 studies met our inclusion criteria. Sildenafil was the most commonly 
studied agent, followed by tadalafil and vardenafil. Most trials found that the PDE-5 inhibitors 
significantly improved exercise capacity and lowered pulmonary pressures. However, there 
were conflicting results regarding these agents’ impact on improving cardiac function and 
functional class. Overall, these medications were effective and well tolerated with a relatively 
benign side effect profile. The PDE-5 inhibitors are an important option in treating PAH. 
While most of the published clinical data involved sildenafil, the other PDE-5 inhibitors show 
promise as well. Further studies are needed to determine the optimal doses of this therapeutic 
drug class, as well as its effects as adjunctive therapy with other agents in PAH.
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Introduction
Pulmonary arterial hypertension (PAH) is a debilitating chronic disease of the small 
pulmonary arteries. The prevalence of PAH varies according to its etiology and among 
specific populations.1 Idiopathic PAH has an annual incidence of one to two cases 
per million.1 The incidence of PAH in scleroderma patients is dramatically higher.2 
  Symptoms are nonspecific and often result in long delays in diagnosis.2 Common 
  clinical manifestations include dyspnea, fatigue, weakness, and low exercise capacity.2 
As the disease progresses, it leads to right ventricular failure and death.3 The estimated 
median survival without medical treatment is approximately 2.8 years.3 Fortunately, 
advances in treatment options have resulted in improved survival.2
The most widely accepted definition of PAH is a mean pulmonary arterial pres-
sure (MPAP) $25 mmHg at rest, normal left-sided filling pressures (pulmonary 
capillary wedge pressure ,15 mmHg), and elevated pulmonary vascular resistance 
(.3 Wood units).3,4 A classification system has evolved and undergone several revi-
sions.5 The most recently updated Dana Point clinical classification from the Fourth 
World Symposium on Pulmonary Hypertension is illustrated in Figure 1.6Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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The development of pulmonary hypertension is a   complex 
and incompletely understood process involving both genetic 
and environmental factors.4 Although significant advances 
in our understanding of PAH have been achieved over 
the past 20 years, much remains unknown regarding the 
pathophysiology.2,7 Pulmonary vascular endothelial   dysfunction 
plays a key role in the development of PAH.2,7 Three identi-
fied neurohormonal pathways involved in this   process are 
endothelin (ET), nitric oxide (NO), and   prostacyclin I2 (PGI2).7 
Pulmonary vasoconstriction may result in an overexpression 
of endothelin-1 (ET-1), as well as a deficiency in either PGI2 
or NO.7 ET-1 is a potent vasoconstrictor that induces cell 
proliferation in vascular smooth muscle and promotes fibro-
sis and inflammation.8 ET-1 stimulates ETA receptors located 
on pulmonary vascular smooth muscle cells as well as ETB 
receptors located on smooth muscle cells and pulmonary 
vascular endothelial cells.3,8 The concentration of intracellular 
calcium increases when ETA receptors are activated, result-
ing in vasoconstriction and proliferation of vascular smooth 
muscle cells.7 Stimulation of ETB   receptors leads to increased 
production of PGI2 and NO, which results in vasodilation 
and plays a role in clearing ET-1.8 NO is a potent vasodilator 
synthesized from L-arginine by NO synthase in lung vascular 
endothelium.8 Production of NO increases intracellular cyclic 
guanosine monophosphate (cGMP), which relaxes vascular 
smooth muscle.7 The lungs have higher concentrations of 
phosphodiesterase-5 (PDE-5) and this enzyme is responsible 
for the degradation of cGMP.7 Prostacyclin is a potent vasodila-
tor with antiproliferative and antiplatelet properties.7 Several 
enzymes are involved in its biosynthesis. Arachidonic acid 
is cleaved from phospholipids by cytosolic phospholipase 
A2 and converted to prostaglandin H2 by the cyclooxygenase 
enzyme. Subsequently, prostaglandin H2 is converted to 
PGI2 by prostacyclin synthase. Prostacyclin further binds to 
endothelial prostacyclin and G protein-coupled receptors which 
increase production of cyclic adenosine 3′,5′-monophosphate 
(cAMP). Higher concentrations of cAMP ultimately result in 
smooth muscle relaxation and   vasodilation.7 Thromboxane A2 
and PGI2 have opposing effects on pulmonary vascular smooth 
muscle and platelet aggregation, which are delicately balanced 
Group 1: Pulmonary arterial hypertension
Idiopathic
Heritable
  BMPR2
  ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)
  Unknown
Drug- and toxin-induced
Associated with:
  Connective tissue diseases
  HIV infection
  Portal hypertension
  Congenital heart diseases
  Schistosomiasis
  Chronic hemolytic anemia
Persistent pulmonary hypertension of the newborn
Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
Group 2: Pulmonary hypertension owing to left heart disease
Systolic dysfunction
Diastolic dysfunction
Valvular disease
Group 3: Pulmonary hypertension owing to lung diseases and/or hypoxia
Chronic obstructive pulmonary disease
Interstitial lung disease
Other pulmonary diseases with mixed restrictive and obstructive pattern
Sleep-disordered breathing
Alveolar hypoventilation disorders
Chronic exposure to high altitude
Developmental abnormalities
Group 4: Chronic thromboembolic pulmonary hypertension
Group 5: Pulmonary hypertension with unclear multifactorial mechanisms
Hematologic disorders (myeloproliferative disorders, splenectomy)
Systemic disorders (sarcoidosis, pulmonary Langerhans cell histiocytosis)
Metabolic disorders (glycogen storage disease, Gaucher disease, thyroid disorders)
Others (tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis)
Figure 1 Updated clinical classification system on the 2008 World Symposium.6
Abbreviations: ALK1, activin receptor-like kinase type 1; BMPR2, bone morphogenetic protein receptor type 2; HIV, human immunodeficiency virus.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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during normal homeostasis. In PAH, a decreased expression 
of prostacyclin synthase results in a reduction of PGI2 levels, 
while thromboxane A2 levels increase; the imbalance of these 
hormones produces pulmonary vasoconstriction.9 It is not clear 
whether one primary pathway is responsible for the development 
and progression of PAH or a combination of these neurohor-
monal abnormalities is involved.7 Ultimately, vasoconstriction in 
conjunction with vascular remodeling and cell proliferation, lead 
to advanced vascular changes, such as the plexiform lesion.10
Currently, there are seven treatments approved by the Food 
and Drug Administration (FDA) available in the US, including 
the prostacyclins (epoprostenol,   treprostinil, iloprost), endothe-
lin receptor antagonists (bosentan, ambrisentan), and PDE-5 
inhibitors (tadalafil, sildenafil).4 Despite the many available 
treatments for PAH, the disease remains incurable and most 
patients will progress to death from right heart failure.2 In the 
absence of a cure for PAH, the ideal treatment would be an 
orally administered agent with few side effects and requiring 
minimal monitoring. It would rapidly and durably improve 
pulmonary blood flow, prevent right heart failure, and improve 
survival as well as quality of life. Lastly, the medication would 
be inexpensive and readily available. Of the currently approved 
therapies, none meet all these criteria.
Despite 15 years of clinical studies, epoprostenol remains 
the only agent to improve survival in   prospective,   randomized 
controlled trials.11,12 However, the   widespread use of the 
prostacyclins may be limited by cost, risk of   infections 
from indwelling catheters, inconvenient   intravenous or 
  subcutaneous administration, and systemic side effects includ-
ing hypotension, headache, diarrhea, and leg pain. Inhaled 
iloprost requires six to nine administrations daily because 
the duration of action only lasts for about 1–2 hours.13 Also, 
patients have been found to be subtherapeutic during the 
  evening hours while sleeping.13 Endothelin receptor antago-
nists are an attractive option. Increasing reports have shown 
these agents to be safe and effective.14 Although ease of 
administration may be considered more alluring over the pros-
tacyclins, adverse effects (eg, hepatotoxicity, teratogenicity, 
edema) and drug interactions may limit their use as well.
The PDE-5 inhibitors are an attractive option among the 
currently available therapies in the management of PAH. 
Over the years, several small, nonrandomized studies as well 
as randomized clinical trials have been published evaluating 
the use of sildenafil in PAH.15–34 More recently, a few   clinical 
trials have also investigated tadalafil, supporting its FDA 
approval for the treatment of PAH.35,36 Compared with the 
prostacyclins and endothelin receptor antagonists, the PDE-5 
inhibitors offer clear advantages as monotherapy in PAH. In 
contrast with the prostacyclins, most patients have few side 
effects, once or thrice daily dosing is convenient, and routine 
laboratory monitoring is not required. Lastly, these agents 
are much less expensive than the alternatives. The purpose 
of this review was to evaluate the safety and efficacy of the 
PDE-5 inhibitors in the management of PAH.
Literature review
A systematic search was conducted using the MEDLINE 
database and the Cochrane Central Register of Controlled 
  Trials for articles published between 1966 and   February 
2010. Searches were limited to English, human, and 
  clinical trial using the terms sildenafil, tadalafil, vardenafil, 
  phosphodiesterase inhibitor, and pulmonary hypertension.
The overall search strategy was to identify clinical   studies 
evaluating the use of oral PDE-5 inhibitors (sildenafil, 
  tadalafil, and vardenafil) in PAH. Articles meeting the follow-
ing criteria were included in this review: study design was a 
randomized controlled trial; subjects included had pulmonary 
arterial hypertension; oral sildenafil, tadalafil, or vardenafil 
was one of the study treatments; and subjects included the 
adult patient population $18 years. Studies were excluded 
if the study population was exclusively done in pediatrics or 
neonates, a PAH subgroup was not included, or the route of 
administration of the PDE-5 inhibitor was not oral.
Two authors (MSB, LMW) independently searched the 
titles and abstracts of potentially eligible studies identified. 
Articles with indeterminate abstracts or potentially   meeting our 
criteria were obtained for full manuscript review and evaluated 
for inclusion criteria. The references of all   identified articles 
were also manually searched to identify additional studies. The 
literature search yielded 10   randomized studies (Table 1). The 
majority of studies involved sildenafil with a few using   tadalafil. 
Only a single, small, randomized study evaluated vardenafil 
compared with the other two PDE-5 inhibitors in PAH.34
Pharmacology
Eleven PDE isoenzymes have been identified, all of which 
have distinct substrates and tissue distribution.37 The PDE-5 
isoenzyme is expressed in the lungs, platelets, vascular smooth 
muscle, and myocardium.37 This enzyme is   responsible for 
degrading cGMP through hydrolysis. Decreased cGMP 
concentrations lead to increased   intracellular calcium, which 
produces smooth muscle vasoconstriction.37 Therefore, 
PDE-5 inhibitors oppose the vasoconstrictive effects within 
the pulmonary smooth muscle by increasing the intracellular 
cGMP concentrations, as well as allowing for enhanced NO-
mediated vasodilatory action.13,38,39Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Sildenafil, tadalafil, and vardenafil are all selective PDE-5 
inhibitors. The selectivity of inhibition for each of these 
agents varies due to differences in their affinity for the PDE 
enzyme.38,40,41 Their relative selectivity for each PDE enzyme 
is measured in terms of drug concentration inhibiting 50% of 
the enzymatic reaction (IC50). The IC50 of sildenafil, tadalafil, 
and vardenafil for PDE-5 are approximately 3.5 nM, 6. nM, 
and 0.1 nM, respectively. The PDE-6 family is localized in 
the retina. Sildenafil has selectivity at PDE-6 in roughly 
10-fold higher concentrations than PDE-5, which may 
explain its impact on vision. Vardenafil has up to 25-fold 
selectivity at PDE-6 compared with PDE-5, which could 
also contribute to ocular adverse effects. Tadalafil does not 
have enhanced selectivity for PDE-6. However, tadalafil has 
selectivity at PDE-11 at 5-fold higher concentrations than at 
PDE-5.38,40,41 PDE-11 is present in skeletal muscle, prostate, 
kidney, liver, pituitary glands, salivary glands, and testes.37 
The clinical significance of the effect of tadalafil on PDE-11 
is unknown.41–43,46
The PDE-5 inhibitors also vary in their pharmacokinetic 
profiles, as illustrated in Table 2. Differences among these 
agents can be seen in their bioavailability, half-life, and 
primary method of elimination. Although these drugs share 
a common mechanism for the primary metabolism of the 
parent drug, dissimilarities exist regarding their metabolites. 
The major metabolite of sildenafil is N-desmethylsildenafil, 
which is half as potent as the parent drug and excreted 80% 
in feces. Tadalafil’s metabolite is considerably less potent 
than the parent drug and is excreted in stool (60%) and urine 
(36%). Renal impairment increases the half-life of both 
tadalafil and its metabolite.47
Large randomized clinical studies
The SUPER (Sildenafil Use in Pulmonary Arterial 
  Hypertension) study was a multicenter, randomized, 
  double-blind, placebo-controlled study investigating the 
short- and long-term outcomes of sildenafil in pulmonary 
hypertension.27 The short-term phase assigned subjects to 
either placebo or one of three sildenafil dosing regimens (20, 
40, or 80 mg three times daily). Those randomized to the 
20 mg and 40 mg groups were initiated on these   regimens 
and continued throughout the 12-week study period   without 
any dose escalation. However, sildenafil was started at 
40 mg orally three times daily for the first seven days after 
enrollment before titrating the dose up to 80 mg three 
times daily for those in this treatment arm. Subjects not 
  originally assigned to the 80 mg dose group and eligible 
for the   long-term phase of the study were titrated to 80 mg Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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three times daily over a six-week period. Dummy dose 
  escalation was performed in the 12-week and long-term 
phases to maintain blinding. Sildenafil was associated 
with a significant improvement in exercise capacity in all 
three groups over placebo (P , 0.001). Sildenafil signifi-
cantly increased the six-minute walk distance (6MWD) 
at week 12 from   baseline with all three incremental doses 
(45 m, 46 m, and 50 m,   respectively; P , 0.001). The 
placebo, 20 mg, 40 mg, and 80 mg sildenafil groups had 
similar   baseline MPAP   measurements (56 ± 16, 54 ± 13, 
49 ± 13, and 52 ± 16 mmHg,   respectively).   Furthermore, 
hemodynamics significantly improved with sildenafil 
from baseline, while no differences were found with pla-
cebo. Mean pulmonary artery pressure decreased by 2.1 
(P = 0.04), 2.6 (P = 0.01), and 4.7 mmHg (P , 0.001) for 
the 20 mg, 40 mg and 80 mg groups, respectively. While 
all three sildenafil groups   significantly increased cardiac 
index compared with placebo, the greatest increase noted 
was 0.37 L/mi-n/m2 (P , 0.001) in the 80 mg group. How-
ever, differences between active treatment groups did not 
reach statistical significance. The percentage of subjects 
observed to improve their World Health Organization 
(WHO)   functional status by at least one class was 28% 
(P = 0.003), 36% (P , 0.001), and 42% (P , 0.001) in 
the 20 mg, 40 mg, and 80 mg groups, respectively. Those 
completing the one-year follow-up study (n = 222) with 
sildenafil 80 mg three times daily monotherapy showed 
a mean change in 6MWD of 51 m, which was compa-
rable with those results shown after 12 weeks of therapy. 
However, a remaining question this study was unable to 
answer was the optimal dosing for long-term therapy. In 
fact, the extension phase supports the use of higher doses 
of sildenafil for the maintenance of efficacy in walk distance 
and functional class.
The second large randomized, placebo-controlled study 
with sildenafil was PACES (Pulmonary Arterial Hyperten-
sion Combination Study of Epoprostenol and Sildenafil).28 
This trial investigated the long-term effects of concomitant 
sildenafil with intravenous epoprostenol in PAH. This 
study was unique in that PAH subjects had to have been on 
intravenous epoprostenol for at least three months prior to 
randomization without any dose changes within the previous 
four weeks. Epoprostenol dosing was considered optimized 
prior to enrollment in the study. The epoprostenol dose   varied 
from 3–181 ng/kg/min; the median dose in the placebo 
and sildenafil arm was 28 and 29 ng/kg/min, respectively. 
Following randomization, subjects in the sildenafil arm 
were administered 20 mg three times daily for four weeks, 
increased to 40 mg three times daily for another four weeks, 
then titrated to 80 mg three times daily for an additional eight 
weeks. Overall, the addition of sildenafil to epoprostenol 
significantly increased the mean change from the baseline 
6MWD over placebo at week 16 (29.8 m, 95% confidence 
interval [CI] 18.5–41.2; versus 1.0 m, 95% CI -10.9–12.9, 
respectively, P , 0.001). Subgroup analysis found those 
subjects whose baseline 6MWD was ,325 m did not benefit 
significantly from adjunct sildenafil compared with placebo. 
However, sildenafil significantly improved the 6MWD over 
placebo if the baseline distance was $325 m. Also, sildenafil 
with epoprostenol significantly reduced MPAP by 2.8 mmHg 
and increased cardiac output by 0.6 L/min over baseline 
(P , 0.05). In the placebo group, cardiac output and pulmo-
nary artery pressures were stable over the study duration.
The PHIRST (Pulmonary Arterial Hypertension and 
Response to Tadalafil) study was the largest randomized 
trial of tadalafil for the treatment of PAH to date.35 Although 
patients treated with epoprostenol, iloprost, or treprostinil 
were excluded, patients were allowed to continue concomitant 
bosentan therapy. Placebo-corrected change in 6MWD from 
baseline to 16 weeks was the primary efficacy outcome. 
Over 400 subjects were randomized to receive one of five 
  treatments, ie, tadalafil 2.5 mg, 10 mg, 20 mg, 40 mg, or 
placebo once daily. The 10, 20, and 40 mg groups significantly 
increased the 6MWD compared with placebo in a dose-
dependent manner by 20 m (P = 0.047), 27 m (P = 0.028), 
and 33 m (P , 0.001), respectively. The 40 mg dose was 
Table 2 Phosphodiesterase-5 inhibitor pharmacokinetic profile44–46
Drug Bioavailability (%) Time to peak  
onset (hours)
Metabolism 
(metabolite activity)
Half-life  
(hours)
Elimination Protein 
binding (%)
Sildenafil 41 0.5–2 Hepatic (active) 4 Fecal (80%) 
Renal (13%)
96
Tadalafil N/A 2–8 Hepatic (inactive) 15 Fecal (61%) 
Renal (36%)
94
Vardenafil 15 0.5–2 Hepatic (active) 4–5 Fecal (91%–95%) 
Renal (2%–6%)
95
Abbreviation: N/A, not available.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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the only regimen achieving any significant impact.   Multiple 
predefined subgroups were also analyzed to   compare 6MWD 
distance from baseline to week 16. Significant   improvements 
in 6MWD were observed in treatment-naive patients 
(P , 0.01), WHO Class I/II (P = 0.04), and WHO Class III/
IV patients (P = 0.02). The onset and incidence of clinical 
worsening improved only in the 40 mg group compared 
with placebo (P = 0.041 and P = 0.038, respectively). No 
significant changes were observed between any treatment 
group and placebo in Borg dyspnea score or improvements 
in WHO classification. Quality of life was assessed using two 
survey instruments. A significant improvement was shown in 
the 40 mg group from baseline to week 16 in all sections of 
the EuroQoL-5D questionnaire (P , 0.02) and six of eight 
domains of the Medical Outcomes Study 36-item short form 
version 2 questionnaire (P , 0.01). Pulmonary hemodynam-
ics were measured in 93 patients and showed improvement 
with tadalafil. In the 20 mg and 40 mg groups compared with 
baseline, MPAP was reduced (-8.5 mmHg, 95% CI -13 to -4, 
P , 0.001 and -4.3 mmHg, 95% CI -8 to -1; respectively, 
P = 0.01). Pulmonary vascular resistance also decreased in the 
20 and 40 mg groups compared with baseline (-254 dyne/s/
cm-5, 95% CI -388 to -120, P = 0.001, and -209 dyne/s/cm-5, 
95% CI -406 to -13, P = 0.039,   respectively). A significant 
increase in cardiac index by 0.6 L/min/m2 was observed in the 
40 mg group compared with baseline (P = 0.028). An exten-
sion of the study evaluated the 20 mg and 40 mg doses beyond 
the initial 16-week study period. The long-term follow-up 
showed tadalafil had sustained favorable effects on exercise 
capacity for at least 10 months.
Small randomized clinical studies
Sildenafil
One randomized study evaluated sildenafil’s effects on 
  exercise capacity, functional class, and resting pulmonary 
artery pressures.29 Although this small trial included New 
York Heart Association (NYHA) Class II–IV subjects, 
only one subject was classified as Class IV at baseline. 
  Furthermore, one subject had pulmonary hypertension 
secondary to thromboembolism. All subjects underwent 
physical, laboratory, and electrocardiogram evaluations at 
baseline. Pulmonary pressures were estimated using Doppler 
studies. All vasodilator medications were discontinued one 
week prior to study entry. Subjects were then randomized 
to either sildenafil or placebo groups for two weeks prior. 
Following a two-week washout period, subjects were crossed 
over to the other study group to complete an additional 
two-week evaluation. A significant improvement in the 
6MWD from baseline (163.89 ± 110.73 m) was found with 
sildenafil compared with placebo (266.67 ± 131.45 versus 
170.0 ± 105.0 m, respectively, P , 0.005). Also, sildenafil 
was associated with a significant reduction in the MPAP from 
baseline (80.78 ± 21.30 mmHg) after two weeks of treatment 
over placebo (55.33 ± 16.52 versus 75.33 ± 19.75 mmHg, 
respectively, P , 0.005). Although no significant improve-
ment was observed with sildenafil on functional class, the 
lack of benefit may be explained by the low number of study 
subjects.
Another small study investigated exercise capacity, 
cardiac function, pulmonary pressures, and quality of life 
scores associated with sildenafil over a six-week period.30 
Although this study included NYHA Class II and III sub-
jects, over 80% were Class II at baseline. Also, the median 
duration of PAH symptoms was about 30 months prior to 
study enrollment. After baseline assessments, subjects were 
randomized to either sildenafil or placebo. The sildenafil 
regimens were weight-based, ie, 25 mg orally three times 
daily (#25 kg), 50 mg orally three times daily (26–50 kg), 
and 100 mg orally three times daily ($51 kg). Patient assess-
ments were performed every two weeks for six weeks in 
both groups. Subjects were crossed over to the other treat-
ment group and again followed up for another six weeks. 
Although digoxin, diuretics, and oral anticoagulants were 
allowed, all other PAH-specific therapies were prohibited 
during the study period. Exercise capacity was measured 
as time on the treadmill rather than the 6MWD. Exercise 
time significantly improved with sildenafil compared with 
placebo (686.82 ± 224.02 versus 475.05 ± 168.02 seconds, 
  respectively, P , 0.0001) at the end of six weeks over baseline 
(440.09 ± 172.17 seconds). Cardiac index also significantly 
improved from baseline (2.83 ± 1.06 L/m2) with sildenafil 
compared with placebo (3.45 ± 1.16 versus 2.80 ± 0.90 L/
m2, respectively, P , 0.0001). However, systolic pulmonary 
artery pressures did not significantly improve from baseline 
with sildenafil (107.36 ± 24.98 versus 98.50 ± 24.38 mmHg, 
respectively, P = 0.09). A significant improvement in quality 
of life scores were also observed with sildenafil over placebo. 
One major limitation to this study was the lack of a washout 
period due to the crossover design. Despite the effects of 
sildenafil possibly being carried into the placebo group after 
subjects finished the active treatment, it is doubtful those 
effects would have been present at the end of the six-week 
study period.
The SERAPH (Sildenafil versus Endothelin Receptor 
Antagonist for Pulmonary Hypertension) study was a ran-
domized, double-blind trial directly comparing the effects of Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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sildenafil and bosentan.31 Patients were included if the MPAP 
was .25 mmHg at rest, 6MWD was 150–450 m, and if they 
were symptomatic despite the use of diuretics, digoxin, and 
anticoagulants. The primary outcome was change in right 
ventricular mass from baseline, with secondary outcomes of 
exercise capacity, cardiac index, and quality of life. Subjects 
were randomized to receive active treatment for a total of 
16 weeks. Both sildenafil 50 mg and bosentan 62.5 mg were 
administered orally twice daily for four weeks. Sildenafil 
subjects were titrated to 50 mg three times daily and bosentan 
subjects were titrated up to 125 mg twice daily. All subjects 
entered the open-label bosentan phase of the study during 
the fifth and final month. Right ventricular mass at baseline 
for the sildenafil and bosentan groups was 159.8 ± 17.2 and 
134 ± 13.1 g, respectively. No significant difference was 
found between sildenafil and bosentan in regard to right ven-
tricular mass reduction from baseline on an intention-to-treat 
analysis. However, per protocol analysis found that sildenafil 
was superior to bosentan in reducing right ventricular mass 
8.1 g reduction with sildenafil (P = 0.016) compared with no 
change with bosentan (P = 0.172). No significant differences 
were observed between treatment groups for exercise capac-
ity and cardiac function. However, both treatment groups had 
significantly improved 6MWD and quality of life scores over 
baseline. Although pulmonary pressures were not directly 
measured in this study, right ventricular mass reduction may 
indicate a physiologic response from lowered pulmonary 
vascular resistance. The clinical significance of the primary 
endpoint remains unknown, since right ventricular mass is 
not a commonly measured endpoint in PAH studies. None-
theless, both interventions resulted in similar improvement 
in exercise capacity.
Another study was conducted to investigate sildenafil 
therapy in Eisenmenger’s syndrome and idiopathic PAH 
patients.32 This study included 20 patients, half with idiopathic 
PAH and half with Eisenmenger’s syndrome. Some of the 
patients were children, although the breakdown by age was 
not provided. This crossover design study included a six-
week, randomized, placebo-controlled portion followed by 
a two-week washout and then a crossover for another six 
weeks. Adults randomized to sildenafil were administered 
25 mg with another 25 mg given six hours later. Sildenafil 
was continued at 100 mg orally three times daily for six weeks 
in those subjects not experiencing hypotension following the 
two initial doses. Children were given sildenafil starting at 
3.125 mg and titrated to a final dose of 25 mg three times 
daily or 6.25 mg titrated to a final dose of 50 mg three times 
daily for those weighing ,30 kg and .30 kg, respectively. 
The 6MWD at baseline was 262 ± 99 m and increased sig-
nificantly both with placebo (293.4 ± 89.4 m, P , 0.009) 
and sildenafil (358.0 ± 96.5 m, P , 0.0001). Pulmonary 
artery systolic pressure was estimated by   echocardiography, 
and fell significantly after six weeks of active treatment 
(98.9 ± 20.5 mmHg versus 78.3 ± 15.3 mmHg, respectively, 
P , 0.0001). In addition, sildenafil significantly improved 
the 6MWD, functional class, and exercise duration compared 
with placebo in both the idiopathic PAH and Eisenmenger 
groups.
Adjunctive sildenafil therapy
The acute effects of sildenafil combined with inhaled 
  iloprost have been studied in severe pulmonary hypertension 
patients.33 Although the functional class of these subjects 
was not specified as an inclusion criteria nor was it disclosed 
as part of baseline characteristics, the investigators defined 
“severe” pulmonary hypertension as MPAP . 40 mmHg. 
All subjects received short-term vasodilator testing, which 
required inhaled NO (iNO) 20–40 ppm to produce a 
  maximum response. Following the return of hemodynamic 
variables to baseline, all subjects received nebulized 2.8 µg 
of iloprost over four minutes, with hemodynamics measured 
at five intervals up to 90 minutes after administration. All 
subjects were then randomized to the following treatment 
groups after hemodynamic variables returned to baseline, 
ie, oral sildenafil 12.5 mg alone, inhaled iloprost 2.8 µg 
an hour after oral sildenafil 12.5 mg, oral sildenafil 50 mg 
alone, or inhaled iloprost 2.8 µg an hour after oral sildenafil 
50 mg. Hemodynamics as well as laboratory sampling was 
measured at multiple intervals up to 180 minutes following 
administration. The greatest improvement in cardiac index 
and pulmonary pressures was found with the combination 
of sildenafil 50 mg and iloprost. There appeared to be a 
dose-response relationship with sildenafil at higher doses, 
resulting in greater improvement. iNO without the addition 
of other agents had the smallest improvement.
Tadalafil
A small randomized, double-blind, crossover study 
  evaluated tadalafil in PAH patients with congenital left to 
right shunts.36 Eleven patients received tadalafil 20 mg once 
daily or placebo for four weeks, followed by a minimum 
two-week washout period, and concluded with four weeks 
of placebo. The   primary outcome measure was change in 
6MWD from baseline to four weeks after tadalafil and after 
placebo. Patients on tadalafil showed a significant increase 
in 6MWD, walking 136.38 m versus 46.5 m on placebo Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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(P = 0.001). Borg dypsnea score decreased significantly in 
the tadalafil group compared with placebo (P = 0.021). No 
significant changes in WHO class were observed, but six of 
eight patients who completed the study improved by at least 
one WHO class on tadalafil. The sole hemodynamic measure 
evaluated was pulmonary artery systolic pressure estimated 
by echocardiography.   Pulmonary artery systolic pressure 
decreased 25.38 mmHg in the tadalafil group compared with 
4.63 mmHg in the placebo group (P = 0.003).
Direct comparison among sildenafil, 
tadalafil, and vardenafil
One study directly compared the short-term effects on 
  cardiopulmonary hemodynamics and gas exchange of the 
three currently available PDE-5 inhibitors in PAH.34 All 
subjects were administered short-term iNO 20–40 ppm to 
produce maximum pulmonary vasodilator responses. Once 
hemodynamic measurements returned to baseline, subjects 
were randomized into one of six treatment groups, ie, 
  sildenafil 50 mg, tadalafil 20 mg, tadalafil 40 mg, tadalafil 
60 mg, vardenafil 10 mg, and vardenafil 20 mg. Only one dose 
of the study medication was administered in each treatment 
group, with observation up to 120 minutes. All study groups 
as well as iNO significantly decreased MPAP from baseline 
except in the tadalafil 60 mg group. iNO and sildenafil 
reduced MPAP by 9.8 (95% CI 7.2–13.3) and 16.2 mmHg 
(95% CI 11.6–21.4), respectively. Both the vardenafil 
10 mg and 20 mg doses significantly decreased MPAP from 
baseline by 14.3 (95% CI 5.6–23.1) and 12.1 mmHg (95% 
CI 7.3–15.8), respectively. Tadalafil was found to decrease 
MPAP significantly in the 20 mg (-12.6 mmHg, 95% CI -2.8 
to -24.4, P , 0.01) and 40 mg groups (-18.3 mmHg, 95% CI 
-13.3 to -21.8, P , 0.001), whereas the 60 mg dose did not 
show benefit (-10.0 mmHg, 95% CI -22.2–2.0, P = NS). Fur-
thermore, sildenafil and iNO significantly improved   arterial 
oxygenation as well as mixed venous oxygen   saturation, 
while vardenafil and tadalafil did not.
Safety and tolerability
Overall, the PDE-5 inhibitors have been shown to be well toler-
ated with minimal adverse events. The tadalafil   discontinuation 
rate was about 16% across all study groups in the PHIRST 
trial.35 Three deaths occurred during the study period, one in 
the placebo group due to worsening PAH, one in the 10 mg 
  (sudden death), and one in the 20 mg (hematophagic histiocy-
tosis syndrome) group. The most frequently reported adverse 
events were headache, myalgia, and flushing. More frequent 
adverse events occurred in the higher-dose groups, with head-
ache being more prominent.35 There were no deaths and no 
significant adverse events related to the study drug in patients 
with PAH associated with congenital heart disease.36
The majority of the smaller sildenafil studies reported no 
major adverse events and none of the subjects discontinued the 
study drug due to side effects.29–34 However, in the two largest 
clinical trials with sildenafil, 1.4% and 5% of subjects with-
drew from treatment with sildenafil due to adverse events.27,28 
In the latter study, the withdrawal rate in the sildenafil group 
was not statistically different than the placebo group.28 Only 
three subjects experienced serious adverse events related to 
sildenafil, which included hypoxia (n = 1) and hypotension 
(n = 2). The serious adverse event rate was similar to the 
placebo group (n = 2). Most of the side effects with sildenafil 
treatment were considered mild to moderate in nature, con-
sisting of headache, nausea, extremity pain and numbness, 
insomnia, and back pain.28,30 The only study evaluating vard-
enafil showed the 20 mg dose was associated with flushing 
and light headache in three of the nine patients, whereas none 
were reported with the 10 mg regimen.34 Although the PDE-5 
inhibitors studies for PAH did not report any adverse events 
with vision or hearing, several reports of serious side effects 
with these medications have been observed in the erectile 
dysfunction trials. Specifically, anterior nonischemic optic 
neuropathy and decreased hearing have been reported.13
Discussion
In summary, there are many smaller studies and two 
  well-designed larger studies supporting the safety and 
  efficacy of sildenafil in PAH. A single, large, well-designed 
study and a small crossover study showed that tadalafil is also 
safe and effective. All studies investigating sildenafil’s effect 
on exercise capacity consistently demonstrated   significant 
improvements in walk distance and time.27–32 MPAP 
  reduction was shown in most studies.27–29,32–34 In contrast with 
the vast majority of studies reported, only a single poorly 
designed study of sildenafil in a mixed adult and pediatric 
population did not show improvements in hemodynamics.30 
Among studies reporting invasively measured hemodynam-
ics, beneficial effects were consistently seen. The absolute 
increase in cardiac index was about 0.3 L/min for most of 
these studies with the greatest increase reported in one study 
of about 0.6 L/min.27,30,33 However, comparisons among trials 
are particularly difficult because the sample size and study 
design were very different in the various studies described.
A key clinical issue that remains unanswered is the optimal 
dose of sildenafil. Several studies used higher sildenafil doses 
than those recommended by the FDA (ie, 20 mg three times Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
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daily). Subjects were titrated to sildenafil 80 mg orally three 
times daily in two studies and 100 mg orally three times daily 
in two more trials.27,28,30,32 The other studies either evaluated the 
effects of only one dose administration or used lower dosing 
regimens (25 mg twice daily or 50 mg three times daily).29,31,33,34 
Some evidence suggests that the 80 mg three times daily regi-
men may offer added benefit over lower doses.27 Thus, the 
optimal dosing regimen for sildenafil remains controversial. 
Although there are inadequate data to draw firm conclusions, 
it is now common practice among many experts to increase 
the sildenafil dose over time in PAH patients.
Role in therapy
Selection of the specific therapies in PAH has become more 
complex as more medications are now available. Clinicians 
attempt to balance efficacy, safety, toxicity, and ease of 
administration in crafting regimens. Recently   published 
guidelines offer evidence-based suggestions based on 
functional class.48 However, data comparing various active 
regimens are lacking.4 The PDE-5 inhibitors remain an 
attractive option for initial therapy in Class II and III patients. 
Furthermore, the lower cost and lack of required monitoring 
makes them particularly attractive. In patients with difficult 
phlebotomy, such as pediatric and chronically ill patients, the 
lack of laboratory monitoring is an   important advantage. In 
more advanced disease, most experts still rely on continuously 
infused prostacyclins as the preferred first-line agents.
An ample body of evidence exists to support the use 
of both sildenafil and tadalafil in PAH. However, there are 
  inadequate data to recommend vardenafil.   Sildenafil and 
  tadalafil are   recommended as first-line therapy (Grade A and B, 
  respectively) for Class II PAH patients over the prostacyclins.48 
Sildenafil and tadalafil are also options as first-line therapy 
(Grade A and B, respectively) in Class III patients.48 Sildena-
fil’s role as monotherapy is less   certain in Class IV patients.48 
Based on the PACES study, the   addition of sildenafil to epo-
prostenol in severe PAH may be recommended.28
Future studies
Compared with where we were 20 years ago, the field of PAH 
has made tremendous progress. However, there remains no 
cure and most patients will die from their disease. As we look 
ahead, new studies will hopefully introduce new medications 
active at different targets. Furthermore, the optimal com-
bination of the different agents remains unclear. Currently 
enrolling and planned studies will hopefully shed further 
light on the optimal management of PAH.
Conclusion
Among the therapies currently available for the treatment 
of PAH, the PDE-5 inhibitors are a safe, effective, and 
well-tolerated therapeutic option. Sildenafil and tadalafil 
are FDA-approved for the treatment of PAH without respect 
to functional class. However, there is a paucity of data 
regarding vardenafil in PAH, and its use cannot be currently 
  recommended. Whether as upfront therapy or add-on therapy, 
a solid body of research now supports sildenafil and tadalafil 
as key treatments in PAH.
Disclosure
Dr Feldman serves as a consultant to United Therapeutics 
and Gilead and has participated in advisory boards for United 
Therapeutics and Gilead.
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